NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Sandra M SwainGong TangHeather Ann BrauerDavid S GoerlitzPeter C LucasAndré RobidouxBrent T HarrisHanna BandosYuqi RenCharles E GeyerPriya RastogiEleftherios P MamounasNorman WolmarkPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The expression level of ERBB2, ESR1, and a few other genomic markers was highly predictive of pCR after trastuzumab-containing regimens. These findings need to be validated and calibrated in future studies.
Keyphrases
- locally advanced
- genome wide
- rectal cancer
- poor prognosis
- neoadjuvant chemotherapy
- copy number
- phase iii
- epidermal growth factor receptor
- lymph node
- study protocol
- tyrosine kinase
- clinical trial
- current status
- phase ii
- estrogen receptor
- squamous cell carcinoma
- case control
- metastatic breast cancer
- radiation therapy
- binding protein
- genome wide identification
- long non coding rna
- open label
- gene expression
- double blind
- transcription factor